BioStock: First patient dosed in Abliva’s Falcon study

In December Abliva started its phase II study to evaluate KL1333 in patients with primary mitochondrial disease. Earlier this week the company announced that the first patient in the study has been dosed. BioStock contacted Abliva CEO Ellen K. Donnelly to ask what this milestone means for the company.

Read the article at biostock.se:

https://www.biostock.se/en/2023/06/first-patient-dosed-in-ablivas-falcon-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/